Potential Effects of CXCL9 and CCL20 on Cardiac Fibrosis in Patients with Myocardial Infarction and Isoproterenol-Treated Rats
Abstract
:1. Introduction
2. Materials and Methods
2.1. Cell Culture and Reagents
2.2. Blood Samples of Patients with MI
2.3. Protein Array
2.4. ELISA
2.5. TNF-α- and TGF-β-Activated PBMCs
2.6. Hypoxia-Incubated H9c2 Cells
2.7. The Growth and Migration of NHCFs Stimulated by CXCL9 and CCL20
2.8. ISO-Induced MI and Post-MI Cardiac Fibrosis in Rats
2.9. Histology (HE Stain, Trichrome Stain, and Quantification of Fibrotic Area)
2.10. Statistics
3. Results
3.1. Determination of CXCL9 and CCL20 in Patients with MI
3.2. CXCL9, CCL20, and TGF-β Remained Elevated following Reperfusion
3.3. TNF-α and TGF-β Enhanced the Expression of CXCL9 and CCL20 in PBMCs
3.4. The Expression of CXCL9 and CCL20 Was Not Increased by Hypoxia in H9c2 Cells
3.5. CXCL9 and CCL20 Enhanced the Growth and Migration of NHCFs
3.6. Increased Serum CXCL9 and NT-ProBNP in Rats with ISO-Induced Cardiac Fibrosis
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Conflicts of Interest
References
- Thom, T.; Haase, N.; Rosamond, W.; Howard, V.J.; Rumsfeld, J.; Manolio, T.; Zheng, Z.J.; Flegal, K.; O’Donnell, C.; Kittner, S.; et al. Heart disease and stroke statistics--2006 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2006, 113, 85–151. [Google Scholar]
- Burke, A.P.; Virmani, R. Pathophysiology of acute myocardial infarction. Med. Clin. North. Am. 2007, 91, 553–572. [Google Scholar] [CrossRef]
- Talman, V.; Ruskoaho, H. Cardiac fibrosis in myocardial infarction-from repair and remodeling to regeneration. Cell Tissue Res. 2016, 365, 563–581. [Google Scholar] [CrossRef]
- Gulati, A.J.A.; Ismail, T.F.; Guha, K.; Khwaja, J.; Raza, S.; Morarji, K.; Brown, T.D.; Ismail, N.A.; Dweck, M.R.; Di Pietro, E.; et al. Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy. JAMA. 2013, 309, 896–908. [Google Scholar] [CrossRef]
- Frangogiannis, N.G. Inflammation in cardiac injury, repair and regeneration. Curr. Opin. Cardiol. 2015, 30, 240–245. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Shinde, A.V.; Frangogiannis, N.G. Fibroblasts in myocardial infarction: A role in inflammation and repair. J. Mol. Cell. Cardiol. 2014, 70, 74–82. [Google Scholar] [CrossRef]
- Le, Y.; Zhou, Y.; Iribarren, P.; Wang, J. Chemokines and chemokine receptors: Their manifold roles in homeostasis and disease. Cell. Mol. Immunol. 2004, 1, 95–104. [Google Scholar]
- Gyöngyösi, M.; Winkler, J.; Ramos, I.; Do, Q.T.; Firat, H.; McDonald, K.; González, A.; Thum, T.; Díez, J.; Jaisser, F.; et al. Myocardial fibrosis: Biomedical research from bench to bedside. Eur. J. Heart Fail 2017, 19, 177–191. [Google Scholar] [CrossRef] [PubMed]
- Nian, M.; Lee, P.; Khaper, N.; Liu, P. Inflammatory cytokines and postmyocardial infarction remodeling. Circ. Res. 2004, 94, 1543–1553. [Google Scholar] [CrossRef] [PubMed]
- Zarrouk-Mahjoub, S.; Zaghdoudi, M.; Amira, Z.; Chebi, H.; Khabouchi, N.; Finsterer, J.; Mechmeche, R.; Ghazouani, E. Pro- and anti-inflammatory cytokines in post-infarction left ventricular remodeling. Int. J. Cardiol. 2016, 221, 632–636. [Google Scholar] [CrossRef]
- Bujak, M.; Frangogiannis, N.G. The role of TGF-beta signaling in myocardial infarction and cardiac remodeling. Cardiovasc. Res. 2007, 74, 184–195. [Google Scholar] [CrossRef]
- Prabhu, S.D.; Frangogiannis, N.G. The Biological Basis for Cardiac Repair After Myocardial Infarction: From Inflammation to Fibrosis. Circ. Res. 2016, 119, 91–112. [Google Scholar] [CrossRef] [Green Version]
- Keeley, E.C.; Moorman, J.R.; Liu, L.; Gimple, L.W.; Lipson, L.C.; Ragosta, M.; Taylor, A.M.; Lake, D.E.; Burdick, M.D.; Mehrad, B.; et al. Plasma chemokine levels are associated with the presence and extent of angiographic coronary collaterals in chronic ischemic heart disease. PLoS ONE 2011, 6, e21174. [Google Scholar] [CrossRef]
- De Oliveira, R.T.; Mamoni, R.L.; Souza, J.R.; Fernandes, J.L.; Rios, F.J.; Gidlund, M.; Coelho, O.R.; Blotta, M.H. Differential expression of cytokines, chemokines and chemokine receptors in patients with coronary artery disease. Int. J. Cardiol. 2009, 136, 17–26. [Google Scholar] [CrossRef]
- Mach, F.; Sauty, A.; Iarossi, A.S.; Sukhova, G.K.; Neote, K.; Libby, P.; Luster, A.D. Differential expression of three T lymphocyte-activating CXC chemokines by human atheroma-associated cells. J. Clin. Invest. 1999, 104, 1041–1050. [Google Scholar] [CrossRef] [Green Version]
- Ranjbaran, H.; Wang, Y.; Manes, T.D.; Yakimov, A.O.; Akhtar, S.; Kluger, M.S.; Pober, J.S.; Tellides, G. Heparin displaces interferon-gamma-inducible chemokines (IP-10, I-TAC, and Mig) sequestered in the vasculature and inhibits the transendothelial migration and arterial recruitment of T cells. Circulation 2006, 114, 1293–1300. [Google Scholar] [CrossRef]
- Altara, R.; Gu, Y.M.; Struijker-Boudier, H.A.; Thijs, L.; Staessen, J.A.; Blankesteijn, W.M. Left Ventricular Dysfunction and CXCR3 Ligands in Hypertension: From Animal Experiments to a Population-Based Pilot Study. PLoS ONE 2015, 10, e0141394. [Google Scholar] [CrossRef]
- Khan, A.; Wang, Y.; Schultheiss, H.P.; Moreira, M.C.; Walther, T. Role of Monokine Induced by Interferon Gamma in Discrimination and Prognosis of Patients With Chagas’ Disease and Idiopathic Dilated Cardiomyopathy. J. Cardiovasc. Pharmacol. 2016, 67, 427–432. [Google Scholar] [CrossRef]
- Safa, A.; Rashidinejad, H.R.; Khalili, M.; Dabiri, S.; Nemati, M.; Mohammadi, M.M.; Jafarzadeh, A. Higher circulating levels of chemokines CXCL10, CCL20 and CCL22 in patients with ischemic heart disease. Cytokine 2016, 83, 147–157. [Google Scholar] [CrossRef]
- Kuznetsov, A.V.; Javadov, S.; Sickinger, S.; Frotschnig, S.; Grimm, M. H9c2 and HL-1 cells demonstrate distinct features of energy metabolism, mitochondrial function and sensitivity to hypoxia-reoxygenation. Biochim. Biophys. Acta 2015, 1853, 276–284. [Google Scholar] [CrossRef]
- Van Tonder, A.; Joubert, A.M.; Cromarty, A.D. Limitations of the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay when compared to three commonly used cell enumeration assays. BMC Res. Notes 2015, 8, 47. [Google Scholar] [CrossRef]
- Kumar, M.; Kasala, E.R.; Bodduluru, L.N.; Dahiya, V.; Sharma, D.; Kumar, V.; Lahkar, M. Animal models of myocardial infarction: Mainstay in clinical translation. Regul. Toxicol. Pharmacol. 2016, 76, 221–230. [Google Scholar] [CrossRef]
- Teerlink, J.R.; Pfeffer, J.M.; Pfeffer, M.A. Progressive ventricular remodeling in response to diffuse isoproterenol-induced myocardial necrosis in rats. Circ. Res. 1994, 75, 105–113. [Google Scholar] [CrossRef]
- Gupta, P.; Kanwal, A.; Putcha, U.K.; Bulani, Y.; Sojitra, B.; Khatua, T.N.; Kuncha, M.; Banerjee, S.K. Cardioprotective effect of ritonavir, an antiviral drug, in isoproterenol induced myocardial necrosis: A new therapeutic implication. J. Transl. Med. 2013, 11, 80. [Google Scholar] [CrossRef]
- Farber, J.M. A macrophage mRNA selectively induced by gamma-interferon encodes a member of the platelet factor 4 family of cytokines. Proc. Natl. Acad. Sci. USA 1990, 87, 5238–5242. [Google Scholar] [CrossRef]
- Bracaglia, C.; de Graaf, K.; Pires, Marafon. D.; Guilhot, F.; Ferlin, W.; Prencipe, G.; Caiello, I.; Davì, S.; Schulert, G.; Ravelli, A.; et al. Elevated circulating levels of interferon-gamma and interferon-gamma-induced chemokines characterise patients with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. Ann. Rheum. Dis. 2017, 76, 166–172. [Google Scholar] [CrossRef] [PubMed]
- Lee, A.Y.; Phan, T.K.; Hulett, M.D.; Körner, H. The relationship between CCR6 and its binding partners: Does the CCR6-CCL20 axis have to be extended? Cytokine 2015, 72, 97–101. [Google Scholar] [CrossRef]
- Frick, V.O.; Rubie, C.; Keilholz, U.; Ghadjar, P. Chemokine/chemokine receptor pair CCL20/CCR6 in human colorectal malignancy: An overview. World J. Gastroenterol. 2016, 22, 833–841. [Google Scholar] [CrossRef]
- Vilahur, G.; Hernández-Vera, R.; Molins, B.; Casaní, L.; Duran, X.; Padró, T.; Badimon, L. Short-term myocardial ischemia induces cardiac modified C-reactive protein expression and proinflammatory gene (cyclo-oxygenase-2, monocyte chemoattractant protein-1, and tissue factor) upregulation in peripheral blood mononuclear cells. J. Thromb. Haemost. 2009, 7, 485–493. [Google Scholar] [CrossRef] [Green Version]
- Puhakka, M.; Magga, J.; Hietakorpi, S.; Penttilä, I.; Uusimaa, P.; Risteli, J.; Peuhkurinen, K. Interleukin-6 and tumor necrosis factor alpha in relation to myocardial infarct size and collagen formation. J. Card. Fail. 2003, 9, 325–332. [Google Scholar] [CrossRef]
- Kehmeier, E.S.; Lepper, W.; Kropp, M.; Heiss, C.; Hendgen-Cotta, U.; Balzer, J.; Neizel, M.; Meyer, C.; Merx, M.W.; Verde, P.E.; et al. TNF-a, myocardial perfusion and function in patients with ST-segment elevation myocardial infarction and primary percutaneous coronary intervention. Clin. Res. Cardiol. 2012, 101, 815–827. [Google Scholar] [CrossRef] [PubMed]
- Ellmers, L.J.; Scott, N.J.; Medicherla, S.; Pilbrow, A.P.; Bridgman, P.G.; Yandle, T.G.; Richards, A.M.; Protter, A.A.; Cameron, V.A. Transforming Growth Factor-beta Blockade Down-Regulates the Renin-Angiotensin System and Modifies Cardiac Remodeling after Myocardial Infarction. Endocrinology 2008, 149, 5828–5834. [Google Scholar] [CrossRef] [PubMed]
- Ikeuchi, M.; Tsutsui, H.; Shiomi, T.; Matsusaka, H.; Matsushima, S.; Wen, J.; Kubota, T.; Takeshita, A. Inhibition of TGF-beta signaling exacerbates early cardiac dysfunction but prevents late remodeling after infarction. Cardiovasc. Res. 2004, 64, 526–535. [Google Scholar] [CrossRef]
- Euler, G. Good and bad sides of TGF-beta-signaling in myocardial infarction. Front. Physiol. 2015, 6, 66. [Google Scholar] [CrossRef] [PubMed]
- Yan, X.; Anzai, A.; Katsumata, Y.; Matsuhashi, T.; Ito, K.; Endo, J.; Yamamoto, T.; Takeshima, A.; Shinmura, K.; Shen, W.; et al. Temporal dynamics of cardiac immune cell accumulation following acute myocardial infarction. J. Mol. Cell. Cardiol. 2013, 62, 24–35. [Google Scholar] [CrossRef] [PubMed]
- Bansal, S.S.; Ismahil, M.A.; Goel, M.; Patel, B.; Hamid, T.; Rokosh, G.; Prabhu, S.D. Activated T Lymphocytes are Essential Drivers of Pathological Remodeling in Ischemic Heart Failure. Circ. Heart. Fail. 2017, 10, e003688. [Google Scholar] [CrossRef]
- Nevers, T.; Salvador, A.M.; Velazquez, F.; Ngwenyama, N.; Carrillo-Salinas, F.J.; Aronovitz, M.; Blanton, R.M.; Alcaide, P. Th1 effector T cells selectively orchestrate cardiac fibrosis in nonischemic heart failure. J. Exp. Med. 2017, 214, 3311–3329. [Google Scholar] [CrossRef] [Green Version]
Patients with MI n = 50 | |||
---|---|---|---|
Age, Mean (± sd) (Years) | 58.6 (± 10.4) | ||
Male, n (%) | 44 (88%) | ||
Clinical information, n (%) | |||
Current smoker | 16 (32%) | ||
Diabetes | 13 (26%) | ||
Hypertension | 23 (46%) | ||
Hyperlipidemia | 22 (44%) | ||
Prescribed medications before acute MI | |||
Aspirin | 10 (20%) | ||
ACEI/ARB | 6 (12%) | ||
CCB | 4 (8%) | ||
Beta-blockers | 2 (4%) | ||
Statin | 3 (6%) | ||
Pre-PCI laboratory data, Mean (± sd) | |||
Cr (mg/dL) | 1.18 (± 0.27) | ||
eGFR (mL/min) | 69.2 (± 16.1) | ||
Total cholesterol (mg/dL) | 193.1 (± 35.7) | ||
Triglyceride (mg/dL) | 154.4 (± 63.4) | ||
LDL (mg/dL) | 119.4 (± 27.4) | ||
HDL (mg/dL) | 40.2 (± 9.39) | ||
Hb (g/dL) | 14.1 (± 1.3) | ||
WBC count (/µL) | 9629.7 (± 2630.5) | ||
Platelet (103/µL) | 245.9 (± 60.0) | ||
LVEF (%) | 52.1 (± 6.5) | ||
Angiographic findings, n (%) | |||
Multi-vessels disease | 17 (34%) | ||
Infarct-related artery | |||
Left anterior descending artery | 21 (42%) | ||
Left circumflex artery | 9 (18%) | ||
Right coronary artery | 20 (40%) |
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Lin, C.-F.; Su, C.-J.; Liu, J.-H.; Chen, S.-T.; Huang, H.-L.; Pan, S.-L. Potential Effects of CXCL9 and CCL20 on Cardiac Fibrosis in Patients with Myocardial Infarction and Isoproterenol-Treated Rats. J. Clin. Med. 2019, 8, 659. https://doi.org/10.3390/jcm8050659
Lin C-F, Su C-J, Liu J-H, Chen S-T, Huang H-L, Pan S-L. Potential Effects of CXCL9 and CCL20 on Cardiac Fibrosis in Patients with Myocardial Infarction and Isoproterenol-Treated Rats. Journal of Clinical Medicine. 2019; 8(5):659. https://doi.org/10.3390/jcm8050659
Chicago/Turabian StyleLin, Chao-Feng, Chih-Jou Su, Jia-Hong Liu, Shui-Tien Chen, Han-Li Huang, and Shiow-Lin Pan. 2019. "Potential Effects of CXCL9 and CCL20 on Cardiac Fibrosis in Patients with Myocardial Infarction and Isoproterenol-Treated Rats" Journal of Clinical Medicine 8, no. 5: 659. https://doi.org/10.3390/jcm8050659